22 May 2023 in Nature Reviews Endocrinology
Tremendous progress has been made towards achieving tight glycaemic control in individuals with diabetes mellitus through the use of frequent or continuous glucose measurements. However, in patients who require insulin, accurate dosing must consider multiple factors that affect insulin sensitivity and modulate insulin bolus needs. Accordingly, an urgent need exists for frequent and real-time insulin measurements to closely track the dynamic blood concentration of insulin during insulin therapy and guide optimal insulin dosing. Nevertheless, traditional centralized insulin testing cannot offer timely measurements, which are essential to achieving this goal. This Perspective discusses the advances and challenges in moving insulin assays from traditional laboratory-based assays to frequent and continuous measurements in decentralized (point-of-care and home) settings. Technologies that hold promise for insulin testing using disposable test strips, mobile systems and wearable real-time insulin-sensing devices are discussed. We also consider future prospects for continuous insulin monitoring and for fully integrated multisensor-guided closed-loop artificial pancreas systems.
16 November 2020 in Bioengineering & Translational Medicine
As wearable healthcare monitoring systems advance, there is immense potential for biological sensing to enhance the management of type 1 diabetes (T1D). The aim of this work is to describe the ongoing development of biomarker analytes in the context of T1D. Technological advances in transdermal biosensing offer remarkable opportunities to move from research laboratories to clinical point‐of‐care applications. In this review, a range of analytes, including glucose, insulin, glucagon, cortisol, lactate, epinephrine, alcohol, as well as ketones such as beta‐hydroxybutyrate (BOHB), will be evaluated to determine the current status and research direction of those analytes specifically relevant to T1D management, using both in‐vitro and on‐body detection. Understanding state‐of‐the‐art developments in biosensing technologies will aid in bridging the gap from bench‐to‐clinic T1D analyte measurement advancement.
26 August 2021 in Biosensors and Bioelectronics
VMVíctor Ruiz-Valdepeñas Montiel
Víctor Ruiz-Valdepeñas Montiel
+3